SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest that anti-tumor immunity is induced. The goal of this study is to evaluate if SS1P therapy renders mesothelioma tumors more sensitive to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint blockade. We evaluated the ability of SS1P to induce adenosine triphosphate (ATP) secretion and calreticulin expression on the surface of AE17M mouse mesothelioma cells. Both properties are associated with immunogenic cell death. Furthermore, we treated these tumors with intra-tumoral SS1P and systemic CTLA-4. We found that SS1P increased the release of ATP from AE17M cells in a dose and time-dependent manner. In addition, SS1P induced calreticulin expression on the surface of AE17M cells. These results suggest that SS1P promotes immunogenic cell death and could sensitize tumors to anti-CTLA-4 based therapy. In mouse studies, we found that the combination of anti-CTLA-4 with intra-tumoral SS1P induced complete regressions in most mice and provided a statistically significant survival benefit compared to monotherapy. The surviving mice were protected from tumor re-challenge, indicating the development of anti-tumor immunity. These findings support the use of intra-tumoral SS1P in combination with anti-CTLA-4.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Toxins - 10(2018), 11 vom: 14. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leshem, Yasmin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.09.2019 Date Revised 04.12.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/toxins10110470 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29073973X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29073973X | ||
| 003 | DE-627 | ||
| 005 | 20231225065352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/toxins10110470 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0969.xml |
| 035 | |a (DE-627)NLM29073973X | ||
| 035 | |a (NLM)30441807 | ||
| 035 | |a (PII)E470 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leshem, Yasmin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.09.2019 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest that anti-tumor immunity is induced. The goal of this study is to evaluate if SS1P therapy renders mesothelioma tumors more sensitive to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint blockade. We evaluated the ability of SS1P to induce adenosine triphosphate (ATP) secretion and calreticulin expression on the surface of AE17M mouse mesothelioma cells. Both properties are associated with immunogenic cell death. Furthermore, we treated these tumors with intra-tumoral SS1P and systemic CTLA-4. We found that SS1P increased the release of ATP from AE17M cells in a dose and time-dependent manner. In addition, SS1P induced calreticulin expression on the surface of AE17M cells. These results suggest that SS1P promotes immunogenic cell death and could sensitize tumors to anti-CTLA-4 based therapy. In mouse studies, we found that the combination of anti-CTLA-4 with intra-tumoral SS1P induced complete regressions in most mice and provided a statistically significant survival benefit compared to monotherapy. The surviving mice were protected from tumor re-challenge, indicating the development of anti-tumor immunity. These findings support the use of intra-tumoral SS1P in combination with anti-CTLA-4 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ATP | |
| 650 | 4 | |a Calreticulin | |
| 650 | 4 | |a SS1P | |
| 650 | 4 | |a anti-CTLA-4 | |
| 650 | 4 | |a immunogenic cell death | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a immunotoxins | |
| 650 | 4 | |a mesothelin | |
| 650 | 4 | |a mesothelioma | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a CTLA-4 Antigen |2 NLM | |
| 650 | 7 | |a Ctla4 protein, mouse |2 NLM | |
| 650 | 7 | |a Msln protein, mouse |2 NLM | |
| 650 | 7 | |a SS1(dsFv)PE38 |2 NLM | |
| 650 | 7 | |a Mesothelin |2 NLM | |
| 650 | 7 | |a J27WDC343N |2 NLM | |
| 700 | 1 | |a King, Emily M |e verfasserin |4 aut | |
| 700 | 1 | |a Mazor, Ronit |e verfasserin |4 aut | |
| 700 | 1 | |a Reiter, Yoram |e verfasserin |4 aut | |
| 700 | 1 | |a Pastan, Ira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Toxins |d 2009 |g 10(2018), 11 vom: 14. Nov. |w (DE-627)NLM199735913 |x 2072-6651 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2018 |g number:11 |g day:14 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/toxins10110470 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2018 |e 11 |b 14 |c 11 | ||